Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.40 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1602906 | 0.84 | GRM4 (0.39) | KDM4EALDH1A1HPGDRAB9AHSD17B10 | |
| SCHEMBL13759272 | 0.81 | GRM4 (0.39) | KDM4EALDH1A1HPGDGRM4KMT2A | |
| SCHEMBL13759370 | 0.79 | GRM4 (0.43) | KDM4EALDH1A1GRM4EIF2AK2MAPK14 | |
| SCHEMBL427140 | 0.78 | GRM4 (0.45) | KDM4EALDH1A1HPGDHSD17B10GRM4 | |
| SCHEMBL430538 | 0.77 | GRM4 (0.43) | KDM4EALDH1A1HPGDHSD17B10GRM4 | |
| SCHEMBL430839 | 0.76 | GRM4 (0.42) | KDM4EALDH1A1HPGDHSD17B10GRM4 | |
| SCHEMBL427601 | 0.76 | RAF1 (0.47) | MAPK14KMT2AMAPT | |
| SCHEMBL425505 | 0.76 | GRM4 (0.45) | KDM4EALDH1A1CYP3A4GLAGAA | |
| SCHEMBL431018 | 0.75 | GRM4 (0.46) | KDM4EALDH1A1HPGDHSD17B10GRM4 | |
| SCHEMBL425180 | 0.75 | AURKA (0.42) | KDM4EALDH1A1HPGDHSD17B10GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | KDM4E 3825/4885ALDH1A1 1903/4885CYP3A4 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.